The MedImmune spinout is targeting inflammation and autoimmune diseases, and will be equipped with up to $250m of series A funding.
MedImmune, the research and development subsidiary of pharmaceutical firm AstraZeneca, launched a US-based startup called Viela Bio armed with up to $250m of funding yesterday to develop six of its molecules.
The capital is being provided in a series A round co-led by 6 Dimensions Capital, the venture capital firm co-founded by pharmaceutical company WuXi PharmaTech, along with private equity firm Boyu Capital and hedge fund manager Hillhouse Capital.
Singaporean state-owned investment firm Temasek and alternative fund manager Sirona Capital…
